Optimising diagnosis of viraemic hepatitis C infection: The development of a target product profile

BMC Infectious Diseases

Volumn 17, Issue , 2017, Pages

  Ivanova Reipold, Elena ^a   Easterbrook, Philippa ^d   Trianni, Alessandra ^a   Panneer, Nivedha ^b   Krakower, Douglas ^c   Ongarello, Stefano ^a   Roberts, Teri ^a   Miller, Veronica ^b   Denkinger, Claudia ^a,c  

^a Tuberculosis Program   (Switzerland)

^b Forum for Collaborative HIV Research   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; VIRUS ANTIGEN; VIRUS RNA;

ANALYTIC METHOD; ANTIGEN SPECIFICITY; ARTICLE; CALIBRATION; CONSENSUS DEVELOPMENT; DELPHI STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; POINT OF CARE SYSTEM; PREVALENCE; PRODUCT DEVELOPMENT; PROGRAM FEASIBILITY; SCALE UP; SENSITIVITY ANALYSIS; STRATEGIC PLANNING; SUSTAINED VIROLOGIC RESPONSE; TARGET PRODUCT PROFILE; VIRUS DETECTION; VIRUS HEPATITIS; ECONOMICS; GENETICS; HEPACIVIRUS; INCOME; ISOLATION AND PURIFICATION; METABOLISM; POVERTY; PROCEDURES; RISK FACTOR;

ANTIGENS, VIRAL; DIAGNOSTIC TESTS, ROUTINE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCOME; POVERTY; PREVALENCE; RISK FACTORS; RNA, VIRAL;

EID: 85032748426     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2770-5     Document Type: Article

References (37)

1. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf?ua=1. Accessed June 2017.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42.
3. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1. Accessed June 2017.
4. Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016;8:21-6.
5. Andrieux-Meyer I, Cohn J. Affonso de Araujo E, Hamid S. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet. 2015;3:e676-7.
6. Gilead. Chronic Hepatitis C Treatment Expansion Generic Manufacturing for Developing Countries. August. 2015. p. 2. http://www.gilead.com/~/media/Files/pdfs/other/HCVGenericAgreementFactSheet.pdf. Accessed June 2017.
7. The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir. Available from https://medicinespatentpool.org/mpp-media-post/the-medicines-patent-pool-signs-licence-with-bristol-myers-squibb-to-increase-access-to-hepatitis-c-medicine-daclatasvir/. 2016. Accessed June 2017.
8. Hill A, Bryony S, Dzintars G, Joseph F. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Erad. 2016;2:28-31.
9. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2015;61:1174-82.
10. Denkinger CM, Kessel M. Diagnostics for hepatitis C: an urgent need for action. Lancet Glob Heal. Denkinger et al. Open access article distributed under the terms of CC BY; 2015;3:e195.
11. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov SBI, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743-800.
12. Murtagh M. UNITAID Hepatitis C Diagnostics Technology Landscape 1st Edition. Geneva: 2015. http://unitaid.org/images/marketdynamics/publications/UNITAID-HCV_Diagnostic_Landscape-1st_edition.pdf. Accessed June 2017.
13. Putting HIV and HCV to the Test: A Product Guide for Point-of-Care CD4 and Laboratory-Based and Point-of-Care Virological HIV and HCV Tests. Geneva: Médecins Sans Frontières (MSF); 2015:1-100. http://www.msfaccess.org/sites/default/files/HIV_HCV_Report_Diagnostic_Guide_2015.pdf. Accessed Nov 2016.
14. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect Dis. 2016;62:1043-8.
15. Peterson J, Green G, Lida K, Lee S. Detection of Hepatitis C Core Antigen in the Antibody Negative "Window" Phase of Hepatitis C Infection. Vox Sang. 2000;78:80-5.
16. Chevaliez S, Feld J, Cheng K, Wedemeyer H, Sarrazin C. Clinical utility of Hepatitis C virus core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther. 2016. doi: 10.3851/IMP3042. [Epub ahead of print]
17. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, et al. Hepatitis C virus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol. 2011;51:264-9.
18. Cepheid, Sunnyvale U. Cepheid brochure: Xpert HCV Viral load. http://www.cepheid.com/administrator/components/com_productcatalog/library-files/611eae732b51634d8a7e64878d8222a1-615085cee2245c0c5e547ebff5052119-Xpert-HCV-Viral-Load-Brochure-CEIVD-3043-02.pdf. Accessed Oct 2016.
19. Price CP. Point-of-care testing. Impact on medical outcomes. Clin Lab Med. 2001;21:285-303.
20. Target product profiles and priority digital health products for TB. Geneva: World Health Organization; 2015. http://www.who.int/tb/areas-of-work/digital-health/target-product-profiles/en/. Accessed June 2017.
21. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/135617/1/WHO_HTM_TB_2014.18_eng.pdf?ua=1&ua=1. Accessed June 2017.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry and Review Staff: Target Product Profile - A Strategic Development Process Tool. Rockville MD. 2007. Available from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080593.pdf. Accessed June 2017.
23. STI POCT Meeting report: Point of Care Tests --Target Product Profiles and Research Questions, May 6-8, Annecy, France. http://who.int/reproductivehealth/POTC-TPPs-2016.pdf?ua=1. Accessed June 2017.
24. Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, et al. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis. 2015;211:S39-49.
25. Porrás AI, Yadon ZE, Altcheh J, Britto C, Chaves GC, Flevaud L, et al. Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment. Debrabant A, editor. PLoS Negl Trop Dis Public Libr Sci; 2015;9:e0003697.
26. Price CP. Medical and Economic Outcomes of Point-of-Care Testing. Clin Chem Lab Med. 2002;40:246-51.
27. Hyle EP, Jani I V., Lehe J, Su AE, Wood R, Quevedo J, et al. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. Sansom SL, editor. PLoS Med Public Libr Sci; 2014;11:e1001725.
28. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast. 1999;15:353-75.
29. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994-1002.
30. Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns MP, et al. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol. 2007;39:308-11.
31. Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, et al. Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. Clin Infect Dis. 2015;60:1743-51.
32. Denkinger C, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J. 2013;42:544-7.
33. Sreeramareddy CT, Kishore PV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis. 2009;9:91.
34. Usdin M, Guillerm M, Calmy A. Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. J Infect Dis. 2010;201:S73-7.
35. Ivanova E, Trianni A, Krakower D, Ongarello S, Roberts T, Easterbrook P and Denkinger C. Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. BMC Infect Dis. 2017;17:(Suppl 1). doi: 10.1186/s12879-017-2769-y.
36. Hadziyannis E, Minopetrou M, Georgiou A, Spanou F, Koskinas J. Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol. 2013;26:146-9.
37. Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A. Simplified diagnostic monitoring for Hepatitis C, in the era of Direct Acting Antiviral treatment. Curr Opin HIV AIDS. 2015;10:369-73.